Newsletter Archive
-
06.25.24 -- Labcorp Launches Global Trial Connect To Accelerate Clinical Trials
6/25/2024
06/25/24 Laboratory Network Newsletter
-
06.11.24 -- What You Should Know About The FDA's New Final Rule On LDTs
6/11/2024
06/11/24 Laboratory Network Newsletter
-
05.28.24 -- New FDA Draft Guidance: Data Integrity For In Vivo Bioavailability And Bioequivalence Studies
5/28/2024
05/28/24 Laboratory Network Newsletter
-
05.14.24 -- Cell Counting Is Growing More Important Amid Advanced Therapy's Rise
5/14/2024
05/14/24 Laboratory Network Newsletter
-
04.23.24 -- FDA Warns Industry Of Fraudulent & Unreliable Lab Testing Data In Premarket Submissions
4/23/2024
04/23/24 Laboratory Network Newsletter
-
04.09.24 -- Pivoting To Allogeneic CAR-T Therapies With Celyad Oncology's CMO, Dr. Charlie Morris
4/9/2024
04/09/24 Laboratory Network Newsletter
-
03.26.24 -- Notable Public Comments On The FDA's Proposed Regulation For Laboratory Developed Tests
3/26/2024
03/26/24 Laboratory Network Newsletter
-
03.12.24 -- FDA's CBER Issues Final Guidance For CAR T Cell Products
3/12/2024
03/12/24 Laboratory Network Newsletter
-
02.27.24 -- FDA Issues Final Guidance: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene
2/27/2024
02/27/24 Laboratory Network Newsletter
-
02.13.24 -- FDA Issues Draft Guidance For Cell & Gene Therapy Potency Assurance
2/13/2024
02/13/24 Laboratory Network Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more